This is a Phase 1/2, open-label study designed to evaluate the safety and efficacy of CABA-201 in patients with active IIM or JIIM and to identify an appropriate dose for future studies.
In this study, we want to learn whether adding anifrolumab to standard treatment for people with polymyositis (PM) and dermatomyositis (DM) works better than standard treatment alone. We also want to learn more about how PM and DM affect the body.
Researchers are studying whether a treatment called ALLO329 CAR T cells is safe and works well for adults with autoimmune disease such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).
Researchers are testing a drug called IMVT-1402 to see if it is safe and if it helps people with skin lupus (a type called subacute or chronic cutaneous lupus) with or without lupus that affects the whole body.
This study wants to see if avacopan is safe and works well for people with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. We also want to find out if it helps prevent the disease from coming back.
We are looking for adults to join a national study to help us learn more about how rheumatoid arthritis (RA) develops.
This study wants to find better treatments for people with autoimmune diseases like rheumatoid arthritis (RA). By studying the different types of cells found in people with RA, researchers can learn more about how RA damages joints.
This study wants to learn more about spondyloarthritis, a type of arthritis that causes a lot of inflammation. We are looking for adults who have a parent, sibling, or child who has spondyloarthritis or a similar health problem to join our study.
This study is testing a new injectable medication called anifrolumab to see how safe and effective it is for adults with chronic cutaneous lupus erythematosus (CLE). Our goal is to find better treatments for people living with CLE.
In this study we want to learn more about the effects of the study drug, benralizumab, for treating children with eosinophilic granulomatosis with polyangiitis (EGPA).